Regentatlantic Capital LLC boosted its holdings in Allergan plc (NYSE:AGN) by 6.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,533 shares of the company’s stock after purchasing an additional 803 shares during the period. Regentatlantic Capital LLC’s holdings in Allergan were worth $1,675,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Morgan Stanley raised its stake in shares of Allergan by 22.2% during the third quarter. Morgan Stanley now owns 2,660,131 shares of the company’s stock valued at $506,702,000 after acquiring an additional 483,860 shares during the last quarter. Nordea Investment Management AB purchased a new stake in Allergan in the third quarter worth about $19,917,000. Eubel Brady & Suttman Asset Management Inc. lifted its stake in shares of Allergan by 1.5% in the third quarter. Eubel Brady & Suttman Asset Management Inc. now owns 78,542 shares of the company’s stock worth $14,961,000 after buying an additional 1,137 shares in the last quarter. Wright Investors Service Inc. lifted its stake in shares of Allergan by 24.9% in the third quarter. Wright Investors Service Inc. now owns 3,779 shares of the company’s stock worth $720,000 after buying an additional 753 shares in the last quarter. Finally, NuWave Investment Management LLC lifted its stake in shares of Allergan by 33,488.9% in the fourth quarter. NuWave Investment Management LLC now owns 3,023 shares of the company’s stock worth $404,000 after buying an additional 3,014 shares in the last quarter. 78.03% of the stock is owned by hedge funds and other institutional investors.
AGN opened at $144.07 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.78 and a current ratio of 1.51. Allergan plc has a 1-year low of $125.84 and a 1-year high of $197.00. The company has a market capitalization of $48.56 billion, a price-to-earnings ratio of 8.63, a price-to-earnings-growth ratio of 1.14 and a beta of 1.43.
Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, January 29th. The company reported $4.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.15 by $0.14. The firm had revenue of $4.08 billion during the quarter, compared to analysts’ expectations of $4 billion. Allergan had a negative net margin of 32.28% and a positive return on equity of 8.18%. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same period in the prior year, the company posted $4.86 earnings per share. On average, equities analysts anticipate that Allergan plc will post 16.4 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 15th. Stockholders of record on Friday, February 15th will be paid a $0.74 dividend. The ex-dividend date is Thursday, February 14th. This is a boost from Allergan’s previous quarterly dividend of $0.72. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.05%. Allergan’s dividend payout ratio is 17.26%.
Allergan announced that its Board of Directors has initiated a share buyback program on Tuesday, January 29th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.
Several research analysts have recently issued reports on AGN shares. Guggenheim started coverage on shares of Allergan in a research note on Monday, October 8th. They issued a “buy” rating on the stock. ValuEngine downgraded shares of Allergan from a “sell” rating to a “strong sell” rating in a research note on Friday, December 21st. Credit Suisse Group set a $200.00 target price on shares of Allergan and gave the stock a “buy” rating in a research note on Thursday, December 13th. Raymond James lowered their price objective on shares of Allergan from $232.00 to $198.00 and set a “buy” rating on the stock in a research report on Wednesday, October 31st. Finally, Leerink Swann assumed coverage on shares of Allergan in a research report on Monday, November 12th. They set an “outperform” rating and a $220.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $201.37.
In other news, CFO Matthew M. Walsh acquired 1,000 shares of Allergan stock in a transaction dated Friday, November 16th. The stock was purchased at an average cost of $157.00 per share, with a total value of $157,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.37% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Highlight Press and is the property of of Highlight Press. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://highlightpress.com/2019/02/02/regentatlantic-capital-llc-acquires-803-shares-of-allergan-plc-agn.html.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Further Reading: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.